Piramal Pharma Limited (IN:PPLPHARMA)

:PPLPHARMA

PPLPHARMA

Piramal Pharma Limited

RESEARCH TOOLSreports

Want to see IN:PPLPHARMA full AI Analyst Report?

Piramal Pharma Limited (PPLPHARMA) Price & Analysis

11 Followers

PPLPHARMA Stock Chart & Stats

₹192.65

-₹4.80(-1.92%)

At close: Jan 08 4:00 PM EST

₹192.65

-₹4.80(-1.92%)

Day’s Range― - ―

52-Week Range₹132.50 - ₹220.90

Previous CloseN/A

Volume1.66M

Average Volume (3M)264.14K

Market Cap

₹214.41B

Enterprise Value₹273.41B

Total Cash (Recent Filing)₹7.44B

Total Debt (Recent Filing)₹48.51B

Price to Earnings (P/E)―

Beta0.75

Next Earnings

Aug 05, 2026

EPS Estimate

-0.86

Next Dividend Ex-DateN/A

Dividend Yield0.08%

Share Statistics

EPS (TTM)-0.18

Shares Outstanding1,329,248,200

10 Day Avg. Volume501,791

30 Day Avg. Volume264,138

Financial Highlights & Ratios

PEG Ratio0.12

Price to Book (P/B)2.22

Price to Sales (P/S)2.04

P/FCF Ratio35.50

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)1.41

Revenue Forecast (FY)₹100.93B

Bulls Say, Bears Say

Bulls Say

Revenue GrowthSustained top-line scaling over multiple years indicates durable commercial traction across segments and markets. Larger revenue base supports fixed-cost absorption, investment in capacity and R&D, and strengthens negotiating leverage with suppliers and customers over a 2–6 month horizon and beyond.

Improved Cash GenerationMaterial improvement in operating and free cash flow signals better working-capital management and cash discipline. Positive FCF provides durable optionality to fund capex, reduce leverage, or support CDMO capacity investments without relying solely on external financing.

Diversified Business ModelA three‑pillar model (CDMO, complex hospital generics, OTC consumer) spreads revenue risk and leverages different demand drivers. CDMO contracts offer multi‑year revenue visibility, while hospital generics and OTC provide complementary cash flow profiles and market channels that support long‑term resilience.

Bears Say

Profitability VolatilityRecurrent swings to net losses reduce ability to consistently fund operations internally and undermine predictability of returns. Structural cost pressures, one‑off charges or margin erosion can persist and constrain reinvestment, capital allocation choices, and long‑term return generation.

Rising LeverageMaterial increase in debt elevates interest and refinancing risk, especially alongside earnings volatility. Higher leverage reduces financial flexibility to fund CDMO capacity or absorb regulatory delays, and raises the bar for sustained operational improvement to preserve solvency and investment capacity.

Historical FCF InstabilityAlthough FCF is now positive, prior multi‑year negative free cash flow reflects working‑capital swings and execution risk. If adverse contract timing or margin pressure recurs, cash generation could reverse, limiting sustainable capex, deleveraging, or strategic investments over the medium term.

Piramal Pharma Limited News

Piramal Pharma Receives FDA Form 483 With VAI Observations at U.S. Plant

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has issued an announcement. Piramal Pharma Limited reported that the U.S. FDA...

1M ago

Piramal Pharma Posts FY26 Loss but Sees Recovery Momentum Across Key Businesses

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has shared an announcement. Piramal Pharma reported FY26 consolidated revenue from operations...

2M ago

Piramal Pharma Clears FY26 Results and Strengthens Board, Governance Bench

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) just unveiled an update. Piramal Pharma’s board has approved the audited standalone...

2M ago

Piramal Pharma clears FY26 results and reinforces board continuity

The latest announcement is out from Piramal Pharma Limited ( ($IN:PPLPHARMA) ). Piramal Pharma Limited’s board has approved...

2M ago

Piramal Pharma Clears FY26 Results and Confirms Continuity in Board Leadership

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) just unveiled an update. Piramal Pharma Limited’s board has approved the audited...

2M ago

Piramal Pharma Clears FY26 Results, Renews Top Leadership Bench

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has shared an update. Piramal Pharma Limited’s board has approved the audited...

2M ago

Piramal Critical Care and Blue-Zone Partner to Recycle Waste Anaesthetic Gases

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has issued an announcement. Piramal Critical Care, Inc. and Canada-based Blue-Zone Technologies...

4M ago

Piramal Pharma to Acquire Kenalog Injectable Portfolio from Bristol-Myers Squibb

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has provided an update. Piramal Pharma’s step-down wholly owned subsidiary, Piramal Critical...

5M ago

Piramal Pharma Strengthens Senior Management, Appoints Interim Company Secretary

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has issued an update. Piramal Pharma Limited has expanded its senior management...

5M ago

Piramal Pharma Posts Higher Profit Despite Softer Revenue in Q3 FY26

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has shared an update. Piramal Pharma Limited’s board has approved the unaudited...

5M ago

PPLPHARMA FAQ

What was Piramal Pharma Limited’s price range in the past 12 months?

Piramal Pharma Limited lowest stock price was ₹132.50 and its highest was ₹220.90 in the past 12 months.

What is Piramal Pharma Limited’s market cap?

Piramal Pharma Limited’s market cap is ₹214.41B.

When is Piramal Pharma Limited’s upcoming earnings report date?

Piramal Pharma Limited’s upcoming earnings report date is Aug 05, 2026 which is in 53 days.

How were Piramal Pharma Limited’s earnings last quarter?

Piramal Pharma Limited released its earnings results on Apr 28, 2026. The company reported ₹0.9 earnings per share for the quarter, missing the consensus estimate of ₹0.96 by -₹0.06.

Is Piramal Pharma Limited overvalued?

According to Wall Street analysts Piramal Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Piramal Pharma Limited pay dividends?

Piramal Pharma Limited pays a Notavailable dividend of ₹0.14 which represents an annual dividend yield of 0.08%. See more information on Piramal Pharma Limited dividends here

What is Piramal Pharma Limited’s EPS estimate?

Piramal Pharma Limited’s EPS estimate is -0.86.

How many shares outstanding does Piramal Pharma Limited have?

Piramal Pharma Limited has 1,329,248,200 shares outstanding.

What happened to Piramal Pharma Limited’s price movement after its last earnings report?

Piramal Pharma Limited reported an EPS of ₹0.9 in its last earnings report, missing expectations of ₹0.96. Following the earnings report the stock price went down -2.637%.

Which hedge fund is a major shareholder of Piramal Pharma Limited?

Currently, no hedge funds are holding shares in IN:PPLPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Piramal Pharma Limited

Piramal Pharma Limited functions as a pharmaceutical enterprise, marketing a diverse array of pharmaceutical products and delivering specialized services, which encompass injectables and high-potency active pharmaceutical ingredient (HPAPI) production. Established in 2020, this company is headquartered in Mumbai, India, and operates as a subsidiary of Piramal Enterprises Limited.